Navigation Links
Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drug
Date:6/3/2011

CHICAGO -- ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators. The study, which looked at tumors from 1,802 patients enrolled in the NCCTG N9831 clinical trial, found that patients with HER2-positive breast cancer and had either a loss of PTEN functioning or normal PTEN activity did equally well when Herceptin was added to chemotherapy to prevent breast cancer recurrence.

VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog. Password: perez

The researchers presented their findings during the American Society of Clinical Oncology Annual Meeting in Chicago.

"This is the largest study to date evaluating PTEN's presence or loss in the context of antiHER2 therapy, and we found no connection," says the study's lead investigator, oncologist Edith Perez, M.D., director of the Breast Clinic at Mayo Clinic in Jacksonville, Fla., and the Serene M. and Frances C. Durling Professor. "Our research team is very pleased to be able to test an important question in treatment of breast cancer and arrive at a definitive answer."

The researchers stained the samples for PTEN expression and linked that data with disease-free survival. They found that PTEN status did not impact disease-free survival significantly; there was only a slightly greater benefit of adding Herceptin for patients with PTEN-tumors.

Preclinical studies and some small patient studies had suggested that tumors with loss of PTEN expression would not benefit from Herceptin, Dr. Perez says. As a result, investigators were considering using PTEN biomarkers in clinical studies as a test of Herceptin resistance, and patients who tested positive for PTEN loss might then be offered other therapies, or invited to participate in clinical trials.

"We have all been interested in biomarkers that predict for benefit to antiHER2 therapy," Dr. Perez says, "but PTEN is not one that we should pursue further, based on our rigorous analysis."

The tumor samples examined in the study came from NCCTG N9831, a phase III randomized, multicenter clinical trial that tested adjuvant Herceptin given with, or following, chemotherapy with paclitaxel, compared with chemotherapy alone.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. In the lab and clinic, VCU Massey develops a new therapy for blood cancers
2. Kreativ Dental Clinic, Offering Dental Implant and Dental Services Abroad, Launches 3D Virtual Tours Online
3. New study looks at disconnect between medical and lay expertise
4. Tie Between Biomarkers, Disease Often Overstated, Scientists Say
5. UCI researchers find link between environment and genetics in triggering MS
6. New study suggests link between estrogen exposure, high blood pressure
7. Temple-led study finds widening gap between distracted driving and legislation
8. Researchers discover link between obesity gene and breast cancer
9. Study Sees Link Between Psoriasis, Obesity in Kids
10. End-of-Life Care Differs Between U.S., Canada, Study Finds
11. Anti-cancer drug discovery partnership formed between UMMC and Ole Miss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... Dr. Jamali is proud to offer this permanent solution to patients who suffer from sleep ... This surgery is performed to correct the alignment of the jaw. It is beneficial for ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Regenerative ... Best Places to Work employee satisfaction survey, earning them second place for Tampa’s Best ... with 25-49 employees. , “This is a great accomplishment for our team,” says ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and ... at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is ... for protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted Reproductive ... are required to report in vitro fertilization (IVF) delivery rates to ... practice of assisted reproductive technologies in the United States. , This year, ...
(Date:4/29/2016)... ... 29, 2016 , ... Orthodontics Limited, one of the nation’s ... Dr. Middleberg, were asked by Invisalign to present an “Ask the ... titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. Gemmi and Dr. Middleberg ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ...  is expected to reach USD 2.06 billion by ... View Research, Inc. Increasing consumer awareness towards a ... over the next seven years.      ... Improper diet intake coupled with rising health treatment ...
(Date:4/26/2016)... -- Hill-Rom Holdings, Inc. (NYSE: HRC ) invites ... Bank 41 st Annual Health Care Conference on Wednesday, ... are invited to listen to the live discussion via the ... at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion ... event and accessible at the links above until August 1, ...
Breaking Medicine Technology: